TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00580112

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone 4 mg orally 24 hrs and 12 hrs before study drug infusion on Day -1, followed by dexamethasone 20 mg intravenously 30 minutes before study drug infusion on Day 1, followed by dexamethasone 4 mg orally 24, 36, 48, 60 and 72 hrs after the start of study drug infusion on Day 1 to 3.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone 4 mg orally 24 hrs and 12 hrs before study drug infusion on Day -1, followed by dexamethasone 20 mg intravenously 30 minutes before study drug infusion on Day 1, followed by dexamethasone 4 mg orally 24, 36, 48, 60 and 72 hrs after the start of study drug infusion on Day 1 to 3.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone 4 mg orally 24 hrs and 12 hrs before study drug infusion on Day -1, followed by dexamethasone 20 mg intravenously 30 minutes before study drug infusion on Day 1, followed by dexamethasone 4 mg orally 24, 36, 48, 60 and 72 hrs after the start of study drug infusion on Day 1 to 3.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trabectedin
Description: Trabectedin 1.3 mg/m\^2 intravenous infusion over 3-hrs every 3 weeks, on Day 1 of each cycle. Each cycle length will be 3 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trabectedin
Description: Trabectedin 1.3 mg/m\^2 intravenous infusion over 3-hrs every 3 weeks, on Day 1 of each cycle. Each cycle length will be 3 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trabectedin
Description: Trabectedin 1.3 mg/m\^2 intravenous infusion over 3-hrs every 3 weeks, on Day 1 of each cycle. Each cycle length will be 3 weeks.
Study: NCT04051684

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transverse abdominal plane block
Description: Regional anesthesia team will perform a single shot TAP block with 0.5% ropivacaine 15-20 ml / side under ultrasound guided technique with blunt tipped, 21 gauge needle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine
Description: Regional anesthesia team will perform a single shot TAP block with 0.5% ropivacaine 15-20 ml / side under ultrasound guided technique with blunt tipped, 21 gauge needle.
Study: NCT01783002

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 11C-Methionine PET/CT scanning
Description: PET with the radiopharmaceutical carbon-11 methionine (11C-MET) has been considered to improve diagnosis due to a superior spatial resolution and higher specificity compared to other radiotracers such as 18F-FDG. For the 11C-MET PET/CT, the patient will receive an intravenous bolus injection of 11C-MET as manufactured at the BCCA production facility at a dose of 6 (0.16 mCi) MBq per kilogram but not to exceed 555 MBq (15 mCi).

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 18F-FDG PET/CT scanning
Description: For PET/CT scans, the patient will first receive an intravenous bolus injection of 18F-FDG as manufactured at the BCCA production facility in a dose determined by body weight but not to exceed 521 MBq (14.1 mCi). Our standard adult prescription (70kg adult) for 18F-FDG is 296 MBq (8.0 mCi). The target dose for body scans is increased by 59.2 MBq (1.6 mCi) for every 20 kg increase in body weight to a maximum target dose of 474 MBq (12.8 mCi).

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SPECT-CT scanning
Description: For the SPECT-CT scan, each injection of intravenous 99mTc-MIBI is dosed at a maximum of 20 mCi (740MBq), as per usual standard of care. The energy window of each scan is at 140 keV, consistent with the standard of SPEC-CT imaging techniques.
Study: NCT02969772

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Assessment of upper limb variables
Description: International Standards for Neurological and Functional Classification of Spinal Cord Injuries of American Spinal Injury Association (ASIA); Functional Independence Measure (FIM); The following kinematic variables of arm were studied: shoulder, elbow and wrist angles; percentage of time to peak velocity; movement time; peak velocity and movement smoothness (number of velocity peaks and index of curvature); Capabilities of Upper Extremity instrument (CUE); Spinal cord independence measure (SCIM II); electromyography (Clavicular portion of pectoralis major, long head of biceps brachii, anterior and posterior deltoid, triceps and wrist extensors).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Training protocol
Description: The strengthening sessions consisted of 20 minutes of electrical stimulation on triceps, extensor carpi radialis longus, extensor digitorum communis, lumbricalis, flexor digitorum superficialis and opponens pollicis muscles. The functional training sessions was performed through movements the reach and palmar grasp with NMES of the several cylindrical and conical objects of different weights (30 minutes sessions).
Study: NCT01069952

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Deep Brain Stimulation System
Description: In DBS, thin wires are used to carry electric current to the parts of the brain involved in depression symptoms. These wires are implanted surgically and are attached to battery operated stimulators usually implanted in the chest. The study doctor will adjust the settings of the electrical stimulation to optimize treatment for each participant.
Study: NCT01852734

Intervention type: PROCEDURE
Group type: OTHER
Intervention: embolizations ,uterine fibroid
Description: 26 patients will be treat with Bead-block microspheres, 500-700 and 700-900µm until flow stop (  cut the tree appearance)~26 patients will be treat with Embosphere, 500-700µm and /or 700-900 until near stasis  flow stop

Intervention type: PROCEDURE
Group type: OTHER
Intervention: embolizations
Description: comparison between the two microspheres
Study: NCT03329534

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gluten free diet
Description: A month long gluten free diet

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Gluten free diet
Description: A month long gluten free diet
Study: NCT01056094

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lutein
Description: Dietary Supplement: 20mg,10mg, 0mg Lutein; daily supplementation 12 week

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lutein
Description: Dietary Supplement: 20mg,10mg, 0mg Lutein; daily supplementation 12 week

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lutein
Description: Dietary Supplement: 20mg,10mg, 0mg Lutein; daily supplementation 12 week
Study: NCT01334684

Intervention type: DRUG
Group type: OTHER
Intervention: Metformin
Description: Metformin, pills, 850 mg three times a day for three months
Study: NCT03916042

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reproxalap Ophthalmic Solution (0.25% Novel Formulation) QID to BID
Description: Reproxalap Opthalmic Solution (0.25% Novel Formulation) administered QID for four weeks, followed by BID administration for eight weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle Ophthalmic Solution (0.25% Novel Formulation) QID to BID
Description: Vehicle Ophthalmic Solution administered QID for four weeks, followed by BID administration for eight weeks
Study: NCT03680287

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Within-Subject test of blinded study medication
Description: On the day after each sleep condition (Uninterrupted Sleep and Sleep Disruption), participants will undergo multiple injections of study medication or placebo. This is a double-blind within-subject Phase II trial. As such, study medications must remain blinded. Participants may receive a medication from one or more of the following categories: prescription stimulants, prescription benzodiazepines, prescription opioids, prescription cannabinoids, over-the-counter medications, or placebo (saline). This study uses a within-subject design, such that participants serve as participants' own control.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Within-Subject test of blinded study medication
Description: On the day after each sleep condition (Uninterrupted Sleep and Sleep Disruption), participants will undergo multiple injections of study medication or placebo. This is a double-blind within-subject Phase II trial. As such, study medications must remain blinded. Participants may receive a medication from one or more of the following categories: prescription stimulants, prescription benzodiazepines, prescription opioids, prescription cannabinoids, over-the-counter medications, or placebo (saline). This study uses a within-subject design, such that participants serve as participants' own control.
Study: NCT03314662

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MF59-adjuvanted Quadrivalent Subunit Inactivated Egg-derived Influenza Vaccine (aQIV)
Description: The strain composition is that recommended by the World Health Organization for the 2017-2018 Northern Hemisphere influenza season (WHO, 2017) for quadrivalent vaccines.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Licensed MF59-adjuvanted Trivalent Subunit Inactivated Egg-derived Influenza Vaccine (aTIV-1)
Description: The strain composition is that recommended by the World Health Organization for the 2017-2018 Northern Hemisphere influenza season (WHO, 2017) for trivalent vaccines.
Study: NCT00642746

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Platinum-based antineoplastic chemotherapy agent given intravenously at 85 mg/m2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Chemotherapy agent given intravenously at 180 mg/m2.
Study: NCT01767870

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: FIT-sigmoidoscopy
Description: Advanced colorectal adenoma detection by fecal immunochemical test with sigmoidoscopy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Colonoscopy
Description: Advanced colorectal adenoma detection by colonoscopy
Study: NCT00396149

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Two matching placebo tablets were administered every day over 2 weeks with a 2-day break for the week-end.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rBet v 1
Description: Two tablets (1 placebo + 1 rBet v 1 or 2 rBet v 1) were administered every day over 2 weeks with a 2-day break for the week-end. Administered doses ranged from 50 to 300 µg rBet v 1.
Study: NCT01728883

Intervention type: DEVICE
Intervention: Home vision monitoring using myVisionTrack®
Description: Patients will be asked to test their vision at home twice per week using myVisionTrack® during the study period.
Study: NCT02480179

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: H.E.G. (hematoencephalography) based neurofeedback
Description: H.E.G. is a relatively new neurofeedback technique which, similar to fMRI is based on differential oxygenated blood supply according to regional brain activity.
Study: NCT03674203

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Platelet-Rich Plasma
Description: 1 ml of PRP was distributed in the papillary dermis of the face, repeating the dose at 15 and 30 days.
Study: NCT00607958

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tipranavir/ritonavir (dose reduction)
Description: tipranavir/ritonavir 500/100 BID
Study: NCT01970514

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ARO Spinal System
Description: The device provides an internal axial rotation orthosis (ARO) for patients being surgically treated for herniated nucleus pulposus (HNP).
Study: NCT03220711

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: confocal endomicroscope
Description: This instrument provides real-time endoscopic histology to guide endoscopic biopsy or endoscopic mucosal resection (EMR) in the patient study group during colonoscopies.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorescein
Description: Fluorescent dye used for imaging contrast only.
Study: NCT03054948

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SMOFLipid
Description: SMOFlipid is a lipid emulsion formed using soybean oil, medium chain triglycerides, olive oil, and fish oil.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard therapy
Description: In most cases standard therapy will be IntraLipid.
Study: NCT00581906

Intervention type: RADIATION
Intervention: DCE-MRI, DW-MRI and MRS
Description: Pts undergo DCE-MRI, DW-MRI or 1\^H-MRS studies on either the 1.5T scanner or the 3T MRI scanners. Patients will be grouped based on their treatment: group one will include pts who undergo surgery (we will no longer accrue pts in this group) \& group two will include pts who undergo chemoradiation therapy.Pts who undergo surgery will have pretreatment DCE-MRI, DW-MRI \&/or 1H-MRS studies on the GE 1.5T or 3T MRI scanner. Pts who participate in chemo-radiation therapy protocols will have pretreatment DCE-MRI, DW-MRI \&/or 1H-MRS studies on the 3T Philips MRI scanner in the radiation oncology suite \& will undergo additional recommended weekly DW-MRI including IVIM studies at the same MRI scanner during the course of treatment. Pts will undergo two recommended DCE-MRI studies (unless contraindicated) when possible. 1st intra-treatment DCE-MRI is recommended between the 1st \& 2nd weeks of treatment \& the 2nd intra-treatment DCE-MRI is recommended between the 3rd \& 4th weeks of treatment.
Study: NCT01711684

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diphenylcyclopropenone (DPCP)
Description: Topical application of study drug
Study: NCT00473837

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chloroquine
Description: This is an orange syrup in a 60ml amber coloured glass bottle containing 50mg of chloroquine base per 5mls as the chloroquine phosphate. The syrup was manufactured by Medreich Sterilab Ltd, Avalahalli, Bangalore, India. Chloroquine: weekly treatment of 7.5mg/kg for 90 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo is an orange syrup in a 60ml amber coloured glass bottle containing sucrose syrup base. The syrup was prepared by the Pharmacy department of the Royal Victorial Teaching Hospital and Atlantic Pharmaceuticals Limited, Banjul
Study: NCT01397448

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E3810
Description: E3810 5 mg/day Group: Orally administered E3810 5 mg tablets and E3810 10 mg placebo tablets once daily after breakfast; and orally administered Teprenone 50 mg placebo capsules three times daily after each meal.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E3810
Description: E3810 10 mg Group: Orally administered E3810 5 mg placebo tablets and 10 mg tablets once daily after breakfast; and orally administered Teprenone 50 mg placebo capsules three times daily after each meal.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Teprenone
Description: Teprenone 150 mg/day Group: Orally administered E3810 5 mg placebo tablets and 10 mg placebo tablets once daily after breakfast; and orally administered Teprenone 50 mg capsules three times daily after each meal.
Study: NCT01267383

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sertraline
Description: Sertraline Hydrochloride Tablets 100 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sertraline
Description: Sertraline Hydrochloride Tablets 100 mg
Study: NCT02014142

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Latanoprost Punctal Plug Delivery System (L-PPDS)
Description: Latanoprost Punctal Plug Delivery System (L-PPDS)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Latanoprost Punctal Plug Delivery System (L-PPDS)
Description: Latanoprost Punctal Plug Delivery System (L-PPDS)
Study: NCT02002052

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Concurrent platinum-based chemotherapy
Description: Platinum-based concurrent chemotherapy in both arms

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Concurrent platinum-based chemotherapy
Description: Platinum-based concurrent chemotherapy in both arms

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Standard Radiotherapy, 60 Gy in 30 fractions.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Functional Lung Avoidance Radiotherapy, 60 Gy in 30 fractions
Study: NCT03724578

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Grape Seed Extract mouth wash
Description: participants will use grape seeds extract mouth wash in addition to standard preventive measures

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: standard preventive measures
Description: twice daily brushing with fluoride tooth pate and daily flossing

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: antimicrobial and fluoride mouth wash
Description: using chlorhexidine and fluoride containing mouth wash
Study: NCT04149548

Intervention type: DIAGNOSTIC_TEST
Intervention: ultrasound
Description: Obstetric ultrasound to pregnant women

Intervention type: DIAGNOSTIC_TEST
Intervention: ultrasound
Description: Obstetric ultrasound to pregnant women
Study: NCT03496103

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: ragweed pollen
Description: three hours ragweed pollen in a allergen exposure chamber

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: ragweed pollen
Description: three hours ragweed pollen in a allergen exposure chamber
Study: NCT00226772

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OMS103HP
Description: Maximum of 39 liters of OMS103HP irrigation solution over a maximum of 2 hours

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: Maximum of 39 liters of vehicle irrigation solution over a maximum of 2 hours
Study: NCT04050644

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Preservative Free drop treatment
Description: Patients will use the preservative-free dexamethasone 0.1% 4 times a day in the first week after cataract surgery, 3 times a day in the second week, twice daily in the third week and once daily in the fourth week and diclofenac 0.1% eye drops 3 times daily for 1 day preoperatively and every 15 minutes in the hour before surgery and then 3 times a day for four weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Preserved drop treatment
Description: Patients will use the preserved dexamethasone 0.1% 4 times a day in the first week after cataract surgery, 3 times a day in the second week, twice daily in the third week and once daily in the fourth week and diclofenac 0.1% eye drops 3 times daily for 1 day preoperatively and every 15 minutes in the hour before surgery and then 3 times a day for four weeks.
Study: NCT00825084

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dimebon
Description: dose escalation of single oral doses of 5, 10 and 20 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dimebon
Description: dose escalation of single oral doses of 5, 10 and 20 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dimebon
Description: 10 mg TID of Dimebon for 7 days followed by 20 mg TID of Dimebon for 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dimebon
Description: 10 mg TID of Dimebon for 7 days followed by 20 mg TID of Dimebon for 7 days
Study: NCT02794194

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Proprioceptive training on a whole body vibration platform
Description: The Training programme consisted of three series of 4 exercises of 45 seconds with 45 seconds rest between exercises. In this intervention participants trained with the BOSU® on a Fitvibe Excel Pro vibration platform (Fitvibe, Bilzen, Belgium).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Proprioceptive training with the BOSU® on the floor
Description: The Training programme consisted of three series of 4 exercises of 45 seconds with 45 seconds rest between exercises. In this intervention participants trained with the BOSU® on the floor.
Study: NCT00768235

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: yoga practice
Description: The yoga program comprised 70 min sessions, 3 times/week during 12 weeks
Study: NCT02271854

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Diclofenac sodium gel 1%
Description: Diclofenac sodium gel 1% four times daily (This study is a within-subject design i.e. active drug applied to one leg and placebo to the other leg at the same time. Therefore the study design is not a cross-over).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diclofenac sodium gel 1%
Description: Diclofenac sodium gel 1% four times daily (This study is a within-subject design i.e. active drug applied to one leg and placebo to the other leg at the same time. Therefore the study design is not a cross-over).
Study: NCT02029352

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sinecatechins 10%

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Composition, apart from the active substance, is otherwise identical to the investigational medical product.
Study: NCT02303951

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vemurafenib
Description: Run-In: Day 1-21 960 mg bid orally, Day 22-28 720 mg bid orally Triple-Treatment (week 5 ongoing): 720 mg bid orally
Study: NCT02271854

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo gel four times daily (This study is a within-subject design i.e. active drug applied to one leg and placebo to the other leg at the same time. Therefore the study design is not a cross-over).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo gel four times daily (This study is a within-subject design i.e. active drug applied to one leg and placebo to the other leg at the same time. Therefore the study design is not a cross-over).
Study: NCT03462823

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Osteoconductive scaffold-hamstring tendon composite repair
Description: The device under study is a composite bone substitute composed of a natural mineral matrix of bovine origin, reinforced with biodegradable synthetic polymers and natural collagen derivatives of bovine origin (smartbone, IBI S.A., Switzerland).

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hamstring tendon-only repair
Description: ACL-reconstruction using hamstring autograft with hybrid fixation in accordance with in-house standard of care.
Study: NCT02784132

Intervention type: OTHER
Group type: OTHER
Intervention: Video diversion
Description: The intervention is playing a video on a computer or iPad (using www.youtube.com) while performing fundoscopy.

Intervention type: OTHER
Group type: OTHER
Intervention: Video diversion
Description: The intervention is playing a video on a computer or iPad (using www.youtube.com) while performing fundoscopy.

Intervention type: OTHER
Group type: OTHER
Intervention: Video diversion
Description: The intervention is playing a video on a computer or iPad (using www.youtube.com) while performing fundoscopy.

Intervention type: OTHER
Group type: OTHER
Intervention: Video diversion
Description: The intervention is playing a video on a computer or iPad (using www.youtube.com) while performing fundoscopy.